Oxis Biotech to Discuss its Cancer-Fighting Platforms at Rodman & Renshaw Global Investment Conference
LOS ANGELES, CA / ACCESSWIRE / September 8, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA) announced today that Anthony J. Cataldo, its Chief Executive Officer, will present a corporate overview of the company at the upcoming Rodman & Renshaw Global Investment Conference in New York on Tuesday, September 13th at 5:30 PM.
Mr. Cataldo is expected to discuss the company's path toward commercializing cancer therapies developed by its research partners at the University of Minnesota cancer center. Oxis recently agreed to a major partnership with the University of Minnesota to develop and commercialize cancer therapies using TriKE technology developed by researchers at the university. Last month, the company announced that its partners at the University of Minnesota received the "Reach" award from the National Institutes of Health which recognized technology for commercialization prospects of the promising TriKE cancer-fighting platform.
"The Rodman conference gives Oxis a chance to distance itself from the many Biotech companies that do not have the type of next generation technology of off the shelf "Targeted Immunotherapy" platform technologies that we have licensed from one of the worlds leading creators of disruptive cancer therapies," Cataldo said.
Oxis' partnership with the University Of Minnesota is part of a formula that has succeeded before. Mr. Cataldo used a similar research partnership with the National Cancer Institute as founder of Lion Biotechnologies Inc. (LBIO) in 2011. That company now has a market capitalization of more than $500 million.
"It is becoming clear that off-the-shelf targeted immunotherapy developed by Drs. Vallera and Miller will represent the next wave of excitement in the biotech community," Cataldo said.
The novel TriKE (Tri-specific NK cell engager for B-cell malignancies) technology has several benefits compared to CAR-T therapy, which is very expensive and has been shown to carry significant side effects and cost. Both Kite Pharma (KITE) and Juno Therapeutics Inc. (JUNO) have gained significant attention for their CAR-T efforts.
ABOUT OXIS INTERNATIONAL, INC. - Oxis International, Inc., through a wholly owned subsidiary, Oxis Biotech, Inc., develops innovative drugs focused on the treatment of cancer and other unmet medical needs. Oxis' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-3350 for all B cell malignancies with its novel TRIKE (Tri-specific NK cell engager). OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
FORWARD LOOKING STATEMENTS - Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company website: www.oxis.com
SOURCE: Oxis International, Inc.
Released September 8, 2016